COMBACTE Scientific Papers 2022: Part 2
Last August we lined up the six COMBACTE scientific papers published so far across the four projects. Fast forward to December 2022, COMBACTE added three more publications to its Library, from COMBACTE-MAGNET and COMBACTE-CDI. Find all nine COMBACTE publications below, from newest to oldest.
COMBACTE-CDI
Objective: To compare the awareness and compliance with the recommended strategies for diagnosis and clinical management of CDI across Europe in 2018–2019.
COMBACTE-MAGNET
Objectives: Bacteria have the potential to translocate between sites in the human body, but the dynamics and consequences of within-host bacterial migration remain poorly understood. Here we investigate the link between gut and lung Pseudomonas aeruginosa populations in an intensively sampled ICU patient using a combination of genomics, isolate phenotyping, host immunity profiling, and clinical data.
Objectives: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects.
-
P. aeruginosa was found to translocate from the gut to the patient’s lungs during antibiotic treatment, where it evolved even higher levels of antibiotic resistance.
COMBACTE-NET, results from the ARTHR-IS trial
Objectives: To identify the preoperative and perioperative risk factors associated with post-surgical Staphylococcus aureus prosthetic joint infections (PJI) and to develop and validate risk-scoring systems, to allow a better identification of high-risk patients for more efficient targeted interventions.
COMBACTE-CDI
Objectives: To compare data on the populations with Clostridioides difficile infection (CDI) in hospitals vs the community across 12 European countries. There is a paucity of data on community-based CDI and how these compare with inpatient CDI.
Objectives: While human-to-human transmission of Clostridioides difficile occurs often, other infection sources, including food, animals and environment, are under investigation. We present a large study on C. difficile in a food item in Europe, encompassing 12 European countries (Austria, France, Greece, Ireland, Italy, the Netherlands, Poland, Slovakia, Spain, Sweden, Romania and the United Kingdom).
-
These findings support recommendations for improving diagnosis in patients presenting with diarrhoea in the community, to guide good practice to limit the spread of CDI.
COMBACTE-MAGNET
Objectives: International travel has been recognized as a risk factor contributing to the spread of antimicrobial resistance (AMR). However, tools focused on AMR in the context of international travel and designed to guide decision making are limited. We aimed at developing an evidence-based educational tool targeting both healthcare professionals (HCPs) and international travellers to help prevent the spread of AMR.
Objectives: The increasing burden of candidemia and the emergence of resistance, especially among non-Candida albicans strains, represent a new threat for public health. We aimed to assess the status of surveillance and to identify publicly accessible resistance data in Candida spp blood isolates from surveillance systems and epidemiological studies in 28 European and 4 European Free Trade Association member states.
-
This easy-to-use, annually updated, freely accessible AMR travel tool, is the first of its kind to be developed. For HCPs, it can provide a valuable resource for teaching and a repository that facilitates a stepwise assessment of the risk of AMR spread and strengthen implementation of optimized infection control measures. Similarly, for travellers, the tool has the potential to raise awareness of AMR and outlines preventive measures that reduce the risk of AMR acquisition and spread.
COMBACTE-CARE
Objectives: Successful clinical trials are subject to recruitment. Recently, the REJUVENATE trial, a prospective phase 2a open-label, single-arm interventional clinical trial conducted within the Innovative Medicines Initiative-supported Combatting Bacterial Resistance in Europe-Carbapenem Resistance project, was published, with 85% of the recruitment performed in Spain. We analysed the recruitment success in this trial by establishing a model of recruitment practice.
Related updates
“We Take Bigger Steps Together”
COMBACTE's Last General Assembly
COMBACTE Launches Last Magazine
COMBACTE launched its last magazine at ECCMID 2023 in Copenhagen. The magazine focuses on project’s impact, and features articles and interviews with ...